Chapel Hill, N.C., USA - December 13, 2016, Chapel Hill, N.C., USA - Cempra, a clinical-stage pharmaceutical company, appointed board member David Zaccardelli as acting CEO and promoted David Moore to the newly created position of president and chief commercial officer.
Article continues below
Dr. Zaccardelli is a seasoned industry leader with more than 25 years of experience including executive management and leadership across a wide range of pharmaceutical companies.
From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics. His roles included chief operating officer, chief manufacturing officer and executive vice president, pharmaceutical development and operations.
Prior to joining United Therapeutics, Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 through 2003.
From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome & Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions.
He also served as director of clinical and scientific affairs for Bausch & Lomb Pharmaceuticals from 1996 to 1997.
Prior to joining Cempra as chief commercial officer in 2014, Mr. Moore spent 14 years in commercial leadership roles at Johnson & Johnson's Ortho-McNeil and Janssen Pharmaceutical divisions, where he developed and executed launch plans for several prescription pharmaceuticals for both primary and acute care settings.
He was also responsible for developing payer value platforms for several therapeutic areas including antibiotics, pain and women's health. Following his tenure at Johnson & Johnson, he was chief business officer and vice president of worldwide commercial operations of Tranzyme, Inc., where he was responsible for building the commercial organization, and for business development.
Before joining Cempra, he was the chief business officer of Ocera Therapeutics where he was responsible for developing the commercial plans for an orphan-designated advanced liver disease product for both the community and acute care markets. ■